Jump to main content
Jump to site search


Micellar Nanoformulation of Lipophilized Bortezomib: High Drug Loading, Improved Tolerability and Targeted Treatment of Triple Negative Breast Cancer

Abstract

Bortezomib (BTZ) is the first proteasome inhibitor approved for the treatment of malignant tumors. The current clinical formulation, however, shows fast clearance, low tumor accumulation, and several side effects. Here, we report that micellar nanoformulation of lipophilized bortezomib achieves significantly enhanced drug loading, prolonged circulation time, improved tolerability and targeted treatment of triple negative breast cancer in vivo. Lipophilized bortezomib, bortezomib-pinanediol (BP), was readily prepared in a high yield. Interestingly, cRGD-targeted micelles based on poly(ethylene glycol)-b-poly(trimethylene carbonate-co-dithiolane trimethylene carbonate) achieved a high drug loading content of 8.05 wt.% BTZ equiv. for BP, which was more than 8-fold higher than for BTZ. BP-loaded cRGD-decorated micelles (BP-cRGD-Ms) exhibited a small size (ca. 49 nm), reduction-triggered drug release, and active targeting ability to αvβ3-overexpressing MDA-MB-231 triple-negative breast cancer cells, resulting in a low IC50 of 0.986 μM. The in vivo studies displayed that BP-cRGD-Ms had nearly 20-fold improvement in elimination half-life and 20-fold higher maximum-tolerated dose as compared to free BTZ. The biodistribution and therapeutic studies in MDA-MB-231 tumor-bearing nude mice demonstrated that BP-cRGD-Ms induced significantly better tumor accumulation and inhibition while lower adverse effects than free BTZ, leading to greatly improved mice survival rate. This micellar nanoformulation of lipophilized bortezomib appears to be a novel and effective strategy to achieve targeted tumor chemotherapy with bortezomib.

Back to tab navigation

Supplementary files

Publication details

The article was received on 12 May 2017, accepted on 14 Jun 2017 and first published on 14 Jun 2017


Article type: Paper
DOI: 10.1039/C7TB01297G
Citation: J. Mater. Chem. B, 2017, Accepted Manuscript
  •   Request permissions

    Micellar Nanoformulation of Lipophilized Bortezomib: High Drug Loading, Improved Tolerability and Targeted Treatment of Triple Negative Breast Cancer

    K. Wu, R. Cheng, J. Zhang, F. Meng, C. Deng and Z. Zhong, J. Mater. Chem. B, 2017, Accepted Manuscript , DOI: 10.1039/C7TB01297G

Search articles by author

Spotlight

Advertisements